Loading...
Loading...
India's itraconazole imports from JAPAN total $992 across 5 shipments from 2 foreign suppliers. JANSSEN PHARMACEUTICAL K.K leads with $832 in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include JOHNSON & JOHNSON PRIVATE LIMITED. This corridor reflects India's pharmaceutical import demand for itraconazole โ a concentrated sourcing relationship with select suppliers from JAPAN.

JANSSEN PHARMACEUTICAL K.K is the leading Itraconazole supplier from JAPAN to India, with import value of $832 across 4 shipments. The top 5 suppliers โ JANSSEN PHARMACEUTICAL K.K, JANSSEN PHARMACEUTICAL K.K. โ collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) ยท Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | JANSSEN PHARMACEUTICAL K.K | $832 | 4 | 83.9% |
| 2 | JANSSEN PHARMACEUTICAL K.K. | $160 | 1 | 16.1% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | JOHNSON & JOHNSON PRIVATE LIMITED | $992 | 5 | 100.0% |
JAPAN โ India trade corridor intelligence
As of April 2026, the Japan to India shipping corridor is experiencing moderate congestion at major ports such as Jawaharlal Nehru Port Trust (JNPT), Chennai, and Mundra. Average sea freight transit time is approximately 7 days, with air freight taking about 3 days. Freight rates have seen a slight increase due to global shipping challenges. The exchange rate between the Japanese Yen and Indian Rupee remains stable, facilitating trade.
The Indian government's Production Linked Incentive (PLI) scheme, introduced in 2024, aims to enhance domestic manufacturing capabilities, potentially reducing reliance on imports. However, the impact on finished formulation imports from Japan is yet to be fully realized, as the PLI scheme primarily targets domestic production.
India and Japan maintain strong bilateral trade relations, with ongoing discussions to enhance pharmaceutical trade. While there is no Free Trade Agreement (FTA) between the two countries, mutual recognition of Good Manufacturing Practices (GMP) is under consideration to facilitate smoother trade.
The landed cost of importing Itraconazole formulations from Japan to India includes the following components:
The total landed cost per unit is calculated by summing all the above components and dividing by the number of units imported.
CDSCO registration, import licensing, and quality testing requirements
To import finished pharmaceutical formulations containing Itraconazole into India, the foreign manufacturer must obtain a Registration Certificate from the Central Drugs Standard Control Organization (CDSCO). This involves submitting Form 40/41, along with a valid manufacturing license, Good Manufacturing Practice (GMP) certificate, and a Free Sale Certificate. The application is evaluated by the Drug Controller General of India (DCGI) to ensure compliance with safety, efficacy, and quality standards. The import license, issued by the Directorate General of Foreign Trade (DGFT), is valid for three years.
Imported Itraconazole formulations must undergo quality testing at CDSCO-approved laboratories. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, adhering to ICH Zone IV guidelines, is mandatory. Customs drug inspectors conduct port inspections to verify documentation and sample collection. If a batch fails quality testing, it is subject to rejection or destruction as per regulatory procedures.
Between 2024 and 2026, CDSCO has implemented stricter regulations for imported medicines to prevent the sale of unapproved or illegal drugs in the Indian market. Import registration and licenses have become mandatory for all pharmaceutical imports, including finished formulations. The introduction of the Production Linked Incentive (PLI) scheme aims to boost domestic manufacturing, potentially impacting the volume of finished formulation imports.
Market demand, customs duty structure, and competitive landscape ยท Import duty: 17.10%
India imports finished Itraconazole formulations primarily due to the availability of patented or branded products not manufactured domestically. Specific dosage forms, such as injectables or specialized tablets, may not be produced locally. The domestic market for Itraconazole formulations is substantial, with a total export value of $27.4 million across 285 exporters to 123 countries.
The import duty for Itraconazole formulations under HS Code 30049099 includes a Basic Customs Duty (BCD) of 10%, an Education Cess of 2%, a Secondary Higher Education Cess of 1%, and a Countervailing Duty (CVD) of 6%. The total landed duty amounts to 17.10%. There are no exemptions or concessional rates for imports from Japan.
India sources Itraconazole formulations from Japan due to the high quality and reliability of Japanese pharmaceutical products. Japan's adherence to stringent manufacturing standards and its ability to produce specialized dosage forms provide a competitive advantage. While other countries like China, Germany, and the US also supply Itraconazole formulations, Japan's share in the Indian market remains significant.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports Itraconazole formulations from Japan due to the availability of patented or branded products not manufactured domestically. Specific dosage forms, such as injectables or specialized tablets, may not be produced locally. The high quality and reliability of Japanese pharmaceutical products, along with adherence to stringent manufacturing standards, make Japan a preferred source.
Compared to other suppliers like China, Germany, and the US, Japan offers a competitive advantage in terms of product quality and reliability. Japanese manufacturers adhere to stringent quality control measures, ensuring high-quality products. While other countries may offer lower prices, Japan's reputation for quality and consistency justifies the higher cost for Indian importers.
Indian importers face risks such as single-source dependency, currency fluctuations, regulatory changes, and potential shipping disruptions. Past shortages have occurred due to global supply chain challenges. To mitigate these risks, importers should consider diversifying suppliers and maintaining adequate inventory levels.
Import license checklist, document requirements, quality testing, and compliance
Upon arrival, CDSCO port inspectors collect samples for mandatory batch testing. The process includes sample collection, testing, and reporting, which may take several weeks. If a batch fails quality testing, it is subject to rejection or destruction as per regulatory procedures. Common quality issues from Japan may include discrepancies in labeling or packaging.
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Itraconazole suppliers from JAPAN to India include JANSSEN PHARMACEUTICAL K.K, JANSSEN PHARMACEUTICAL K.K.. The leading supplier is JANSSEN PHARMACEUTICAL K.K with import value of $832 USD across 4 shipments. India imported Itraconazole worth $992 USD from JAPAN in total across 5 shipments.
India imported Itraconazole worth $992 USD from JAPAN across 5 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Itraconazole sourced from JAPAN include JOHNSON & JOHNSON PRIVATE LIMITED. The largest buyer is JOHNSON & JOHNSON PRIVATE LIMITED with $992 in imports across 5 shipments.
The total value of Itraconazole imports from JAPAN to India is $992 USD, across 5 shipments and 2 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records โ the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
5 Verified Shipments
2 suppliers, 1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists